@article{e8c02c474e9c40b5a182df7440336355,
title = "Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group",
abstract = "The 5-year disease-free survival (DFS) of National Cancer Institute (NCI) high-risk (HR) B-lymphoblastic leukemia (B-ALL) patients with end of induction (EOI) minimal residual disease (MRD) ≥0.1% and end of consolidation (EOC) MRD ≥0.01% is 39 ± 7%, warranting consideration of hematopoietic stem cell transplant (HSCT). However, the impact of EOC MRD in NCI standard-risk (SR) B-ALL patients using COG regimens is unknown. We found that SR patients with MRD ≥0.01% at both EOI and EOC have a 4-year DFS/overall survival (OS) of 72.9 ± 19.0%/91.7 ± 10.8% versus 90.7 ± 2.9%/95.5 ± 2.0% (p =.0019/.25) for those with EOI MRD ≥0.01% and EOC MRD <0.01%. These data suggest that routine use of HSCT may not be warranted in EOC MRD ≥0.01% SR patients.",
keywords = "ALL, B-lymphoblastic leukemia, minimal residual disease",
author = "Rau, {Rachel E.} and Yunfeng Dai and Meenakshi Devidas and Rabin, {Karen R.} and Patrick Zweidler-McKay and Anne Angiolillo and Schore, {Reuven J.} and Burke, {Michael J.} and Salzer, {Wanda L.} and Heerema, {Nyla A.} and Carroll, {Andrew J.} and Winick, {Naomi J.} and Hunger, {Stephen P.} and Raetz, {Elizabeth A.} and Loh, {Mignon L.} and Wood, {Brent L.} and Borowitz, {Michael J.}",
note = "Funding Information: This work was supported by grants U10 CA98543, U10 CA98413, U10 CA180886, 1U24‐CA196173, and U10 CA180899 from the National Institutes of Health as well as funding from St Baldrick's Foundation. Sanofi and Bristol‐Myers Squibb were industry sponsors of the therapeutic trials described here. Elizabeth A. Raetz is a KiDS of NYU Foundation Professor at NYU Langone Health. Mignon L. Loh is a UCSF Benioff Chair of Children's Health and Deborah and Arthur Ablin Endowed Chair in Pediatric Molecular Oncology. Stephen P. Hunger is the Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics at the Children's Hospital of Philadelphia. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",
year = "2021",
month = apr,
doi = "10.1002/pbc.28929",
language = "English (US)",
volume = "68",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",
}